What is the shelf life of the targeted drug sotoraxib (AMG510)?

Sotorasiib (AMG510) is a prescription drug, and its shelf life or shelf life is usually strictly controlled by the drug manufacturer during the production process and clearly marked on the drug packaging. Since the shelf life of a drug is affected by many factors, including storage conditions, packaging integrity, and the stability of the drug itself, generally speaking, the shelf life of such targeted drugs is usually longer, possibly more than a few years.

Sotorasiib is a targeted therapy drug targetingKRAS G12C mutation and can be used to treat certain malignant tumors, especially non-small cell lung cancer. KRAS gene mutations occur with high frequency in various cancers, and KRAS G12C mutation is the most common one. By inhibiting the protein encoded by the KRAS G12C mutated gene, sotoracib interferes with the signaling pathways of malignant tumor cells, thereby inhibiting the growth and spread of tumor cells.

For targeted formulations such as biosimilars or small molecule drugs such as sotorasiib, if they are stored unopened and in accordance with the storage conditions recommended by the manufacturer (usually a cool and dry place, avoiding light and freezing), the shelf life can usually be achieved3-5 years or longer. However, once opened, especially after contact with air, the activity of the drug may be reduced, so the shelf life after opening will be shortened accordingly.

When using sotoracib, medical institutions will strictly manage the storage and distribution of the drug to ensure that the drugs received by patients are always within the validity period. Patients should read the drug instructions carefully before use and understand the specific storage conditions and expiration date to ensure the quality and efficacy of the drug. If you find any abnormality in the medicine, such as color change, odor change or crystallization, you should stop using it immediately and consult a doctor.